Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2014
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Zentalis Pharmaceuticals completed enrollment in DENALI Part 2a for its investigational WEE1 inhibitor azenosertib, with dose confirmation expected in the first half of 2026. - The company plans to initiate the confirmatory ASPENOVA Phase 3 trial in the first half of 2026, comparing azenosertib to standard-of-care chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer patients. - DENALI Part 2 topline results are expected by year-end 2026, which could potentially support accelerated approval for treating approximately 50% of platinum-resistant ovarian cancer patients who overexpress Cyclin E1. - Zentalis maintains a strong financial position with $280.7 million in cash and securities, providing an estimated runway into late 2027 to advance this potentially first-in-class oral therapy.
- Zentalis Pharmaceuticals announced four azenosertib abstracts accepted for poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. - The presentations focus on Phase 1 results and Cyclin E1 biomarker findings that support the company's biomarker-driven strategy for treating platinum-resistant ovarian cancer patients. - Azenosertib targets approximately 50% of platinum-resistant ovarian cancer patients who are Cyclin E1-positive, representing an underserved patient population with significant unmet medical need. - The studies highlight azenosertib's potential as both monotherapy and combination therapy across multiple tumor types, including early-line ovarian cancer treatment and HER2-expressing solid tumors.
- Zentalis Pharmaceuticals has appointed James B. Bucher as Chief Legal Officer and Corporate Secretary, effective September 18, 2025, bringing over 30 years of life sciences legal experience. - Bucher previously served as Chief Legal Officer at Harpoon Therapeutics and played a pivotal role in orchestrating the company's acquisition by Merck in 2024. - The appointment comes as Zentalis advances azenosertib, a potentially first-in-class WEE1 inhibitor, into registration-intent clinical trials for ovarian cancer treatment. - Bucher's extensive experience in corporate strategy, mergers and acquisitions, and public company matters will support Zentalis' late-stage development and potential product launch preparations.
- Toronto-based biotech company Radiant Biotherapeutics has named Deborah Geraghty, Ph.D., as President and Chief Executive Officer to lead the company's next phase of growth. - Dr. Geraghty brings over 20 years of financial, operational, and strategic experience in biopharmaceutical leadership, having previously served as President and CEO of Anokion SA. - The company also appointed Stefan Larson, Ph.D., as Chair of the Board of Directors and Ingmar Bruns, M.D., Ph.D., as Board Member to strengthen its leadership team. - The new leadership appointments position Radiant Biotherapeutics for strategic expansion under experienced biotechnology industry executives.
• Zentalis Pharmaceuticals is restructuring to prioritize the late-stage development of azenosertib, a WEE1 inhibitor, for gynecological malignancies. • The restructuring includes a workforce reduction of approximately 40% to extend the company's cash runway into late 2027. • Azenosertib has shown a 5.5-month median duration of response with no new safety signals in mid-trial data from the MAMMOTH and DENALI studies. • Zentalis plans to present updated clinical data and regulatory plans for azenosertib at a corporate event on January 29, 2025.
- Zentalis Pharmaceuticals presented updated clinical data on azenosertib, highlighting its potential in treating Cyclin E1+ platinum-resistant ovarian cancer (PROC). - In the DENALI trial, azenosertib monotherapy demonstrated an objective response rate (ORR) of approximately 35% in heavily pretreated patients with Cyclin E1+ PROC. - The FDA has granted Fast Track Designation to azenosertib for Cyclin E1+ PROC, potentially expediting its development and regulatory review. - Zentalis plans to initiate enrollment for DENALI Part 2 in the first half of 2025, with topline data expected by the end of 2026, aiming for accelerated approval.
• The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies, allowing for the resumption of patient enrollment in ongoing trials. • The decision follows a comprehensive safety assessment review by the FDA, reinforcing confidence in azenosertib's therapeutic potential, especially for gynecologic malignancies. • Azenosertib, an orally bioavailable WEE1 inhibitor, is being evaluated as both a monotherapy and in combination to treat ovarian cancer and other tumor types. • Zentalis plans to present monotherapy data on azenosertib later in 2024, providing updates on clinical development timelines and data presentation.
• The FDA has lifted the partial clinical hold on trials evaluating azenosertib, a WEE1 inhibitor, in patients with advanced solid tumors, allowing studies to resume enrollment. • The hold was initiated in June 2024 due to two deaths from presumed sepsis in the DENALI trial, but the FDA has now reviewed and approved Zentalis Pharmaceuticals' response package. • Azenosertib is being investigated as a monotherapy and in combination for platinum-resistant ovarian cancer and uterine serous carcinoma, with additional data expected in Q4 2024.
• The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies, allowing the company to resume enrollment in ongoing clinical trials. • Zentalis plans to present azenosertib monotherapy data and provide updates on clinical development at a corporate event later this year. • The company remains confident in azenosertib's therapeutic potential for addressing unmet needs in gynecologic malignancies. • Zentalis is on track to meet all previously disclosed data guidance for 2024, including key clinical study results expected in Q4.
